FDA grants accelerated approval to AstraZeneca's Etcamah for certain breast cancers, boosting stock sentiment.

AstraZeneca's drug Etcamah (camizestrant) received accelerated FDA approval for use with CDK4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer patients with ESR1 mutations. This approval follows earlier European clearance and despite a previous negative advisory vote. The drug label includes warnings about heart risks and requires specific patient testing. Citi values the current market opportunity at $112 million, with potential to grow to $6 billion pending results from an upcoming trial expanding the drug's use to a broader patient group.